DANA CHANDLER: Open Payments
NPI 1083258446 · BURLESON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$766 in 39 payments from 15 companies in 2025. Trend: 2023 $830 · 2024 $779 · 2025 $766
Food & beverage: $766
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 7 | $141 |
| SCPHARMACEUTICALS INC. | 5 | $90 |
| Novartis Pharmaceuticals Corporation | 4 | $77 |
| PFIZER INC. | 4 | $74 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Novo Nordisk Inc | 2 | $36 |
| Amgen Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
Products named: VERQUVO, FUROSCIX, LEQVIO, VYNDAQEL, FARXIGA, AREXVY, Repatha, CAMZYOS.
Industry payments across TX — which companies pay providers there.
